Colossal Biosciences in talks to raise capital at $20B-$30B valuation

Colossal Biosciences, the de-extinction company focused on reviving species like the woolly mammoth, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion. This would roughly triple its previous valuation, signaling intense investor interest in its gene-editing and conservation technology. The deal highlights growing confidence in the commercial potential of synthetic biology.

Sources (1)